Wolfgang Abenhardt

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group

Nicolas Moosmann, Ludwig Fischer von Weikersthal, Ursula Vehling‐Kaiser et al. · Journal of Clinical Oncology · 2011 · 117 citations

Medicine, Oncology, Pharmacology +14

Consolidation with alemtuzumab improves progression‐free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long‐term follow‐up of a randomized phase III trial of the German CLL Study Group (GCLLSG)

Carmen D. Schweighofer, Matthias Ritgen, Barbara Eichhorst et al. · British Journal of Haematology · 2008 · 101 citations

Medicine, Immunology, Oncology +15

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group

Manuela A. Hoechstetter, Robert Busch, Barbara Eichhorst et al. · Leukemia · 2017 · 61 citations

Medicine, Oncology, Pharmacotherapy +16

Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry

Andreas D. Hartkopf, Jens Huober, Bernhard Volz et al. · The Breast · 2017 · 61 citations

Medicine, Endocrinology, Oncology +15